(NasdaqGM:MTEX), FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) — Mannatech, Incorporated (NASDAQ: MTEX), (“Mannatech” or “Company”), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 […]
Mannatech Reports Financial Results for Third Quarter 2025 GlobeNewswire November 12, 2025 FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) — Mannatech, Incorporated (NASDAQ: MTEX), (“Mannatech” or “Company”), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results
Canary Funds’ XRP Trust is expected to become the first pure spot XRP (CRYPTO: $XRP) exchange-traded fund (ETF) to begin trading in the U.S. With approval from the U.S. Securities and Exchange Commission (SEC) imminent, the first spot XRP ETF could begin trading in New York on the Nasdaq (NASDAQ: $NDAQ) exchange Nov. 13. Analysts
Analysts at U.S. bank Citigroup (NYSE: $C) forecast that global copper consumption will rise in 2026. Copper consumption increased a modest 1% year-over-year in September 2025, according to market data. The September data showed consumption outside China increased by 2% compared to the same period of 2024. But China’s consumption remained flat year-over-year, proving to
Company Sells 166 Boats in 120 Days, Reduces Floor-Plan Exposure by Over 40%, and Generates $3.9 Million in Real Estate Proceeds Vision Marine Technologies Inc. (NASDAQ: VMAR) (“Vision Marine” or the “Company”), a company specializing in high-voltage marine propulsion and premium boating experiences, today announced substantial progress in strengthening its financial position and operational efficiency
AGNC Investment Corp. (Nasdaq: AGNC) announced today that its Board of Directors has declared a cash dividend of $0.12 per share of common stock for November 2025. The dividend is payable on December 9, 2025 to common stockholders of record as of November 28, 2025. For further information or questions, please contact Investor Relations at
(NASDAQ:MGNX), Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platform Realigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing development in ovarian cancer Cash runway guidance extended into late 2027 ROCKVILLE, Md., Nov. 12,
(NASDAQ:SCWO), Third Quarter Revenues Increased to $0.8 Million Due to Higher Service Revenues and Expects 2025 Full Year Revenues of Approximately $4 Million Fortified Balance Sheet Including $7.0 Million ATM Facility Extends Cash Runway into Q2 2026 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET DURHAM, N.C., Nov. 12, 2025 (GLOBE
(Other OTC:IDXG),(OTC US:IDXG), â— Q3 Revenue of $8.8 million â— Q3 Cash Collections of $10.0 million â— Q3 Thyroid test volume up 12% year-over-year to record levels â— Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ, Nov. 12, 2025 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX:
(NASDAQ:ASND), – Q3 2025 revenue of EUR143.1 million for YORVIPATH(R) and EUR50.7 million for SKYTROFA(R) – Q3 2025 operating profit of EUR11.0 million – TransCon(R) CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – Conference call today at 4:30 pm ET COPENHAGEN, Denmark,